Payment overview · 2025
General Payments
$489.92
23 reported records · 9 companies
Healthcare provider profile · identity verified
Kevin A Vu, M.D
Allopathic & Osteopathic Physicians|Hospitalist · SACRAMENTO, CA · NPI 1760634778
Verified facts
What the public records show
CMS Open Payments records show Kevin A Vu, M.D received $489.92 in general payments during 2025 across 23 reported records.
Gilead Sciences, Inc. accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Vemlidy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $211.39 | 43.1% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.30 | 13.1% | 3 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $41.08 | 8.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.47 | 8.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $33.28 | 6.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.74 | 5.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $26.92 | 5.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.33 | 4.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.41 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $489.92 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $64.30 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.47 | 2 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $33.28 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| AVANTI Normalized: avanti |
Device | CORDIS US CORP. | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.33 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 121 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
103 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
368 | 80 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
195 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
121 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1874 | 552 |
| Losartan Potassium | Losartan Potassium | 1137 | 332 |
| Jardiance | Empagliflozin | 1089 | 228 |
| Amlodipine Besylate | Amlodipine Besylate | 937 | 303 |
| Metformin Hcl | Metformin Hcl | 934 | 257 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 787 | 239 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 753 | 189 |
| Azelastine Hcl | Azelastine Hcl | 704 | 182 |
| Gabapentin | Gabapentin | 687 | 228 |
| Lisinopril | Lisinopril | 593 | 177 |
| Fluticasone Propionate | Fluticasone Propionate | 553 | 162 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 502 | 171 |
| Omeprazole | Omeprazole | 498 | 191 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 482 | 149 |
| Meloxicam | Meloxicam | 450 | 167 |
| Tamsulosin Hcl | Tamsulosin Hcl | 410 | 138 |
| Farxiga | Dapagliflozin Propanediol | 368 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 348 | 109 |
| Simvastatin | Simvastatin | 313 | 95 |
| Furosemide | Furosemide | 302 | 99 |
| Alendronate Sodium | Alendronate Sodium | 293 | 85 |
| Famotidine | Famotidine | 285 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 285 | 84 |
| Metformin Hcl Er | Metformin Hcl | 279 | 98 |
| Trazodone Hcl | Trazodone Hcl | 277 | 92 |
| Finasteride | Finasteride | 275 | 83 |
| Meclizine Hcl | Meclizine Hcl | 273 | 94 |
| Fluocinonide | Fluocinonide | 272 | 59 |
| Loperamide | Loperamide Hcl | 266 | 128 |
| Labetalol Hcl | Labetalol Hcl | 251 | 68 |
| Donepezil Hcl | Donepezil Hcl | 240 | 85 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 236 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 85 |
| Allopurinol | Allopurinol | 227 | 76 |
| Montelukast Sodium | Montelukast Sodium | 219 | 67 |
| Ibuprofen | Ibuprofen | 207 | 73 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 207 | 66 |
| Memantine Hcl | Memantine Hcl | 195 | 70 |
| Vemlidy | Tenofovir Alafenamide | 195 | 32 |
| Raloxifene Hcl | Raloxifene Hcl | 185 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 176 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 42 |
| Ezetimibe | Ezetimibe | 164 | 46 |
| Glipizide Er | Glipizide | 150 | 50 |
| Januvia | Sitagliptin Phosphate | 140 | 24 |
| Hydrocortisone | Hydrocortisone | 136 | 44 |
| Rybelsus | Semaglutide | 121 | 33 |
| Breo Ellipta | Fluticasone/Vilanterol | 119 | 20 |
| Atenolol | Atenolol | 118 | 36 |
| Glipizide | Glipizide | 116 | 39 |
| Metoclopramide Hcl | Metoclopramide Hcl | 116 | 38 |
| Fluvastatin Sodium | Fluvastatin Sodium | 111 | 25 |
| Eliquis | Apixaban | 107 | 24 |
| Celecoxib | Celecoxib | 105 | 31 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 105 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 23 |
| Linzess | Linaclotide | 103 | 14 |
| Carvedilol | Carvedilol | 99 | 34 |
| Benazepril Hcl | Benazepril Hcl | 94 | 34 |
| Baclofen | Baclofen | 91 | 31 |
| Colchicine | Colchicine | 88 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 47 |
| Oxybutynin Chloride | Oxybutynin Chloride | 86 | 25 |
| Vascepa | Icosapent Ethyl | 85 | 20 |
| Myrbetriq | Mirabegron | 84 | 22 |
| Amoxicillin | Amoxicillin | 82 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 31 |
| Azithromycin | Azithromycin | 79 | 75 |
| Naproxen | Naproxen | 78 | 29 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 77 | 16 |
| Acarbose | Acarbose | 76 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 17 |
| Valsartan | Valsartan | 72 | 19 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 66 | 19 |
| Xarelto | Rivaroxaban | 66 | 13 |
| Latanoprost | Latanoprost | 63 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 62 | 25 |
| Procto-Med Hc | Hydrocortisone | 61 | 16 |
| Restasis | Cyclosporine | 59 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 58 | 18 |
| Levetiracetam | Levetiracetam | 58 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 20 |
| Prednisone | Prednisone | 57 | 44 |
| Nifedipine Er | Nifedipine | 55 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 51 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 47 | 12 |
| Nitroglycerin | Nitroglycerin | 47 | 21 |
| Tradjenta | Linagliptin | 46 | 11 |
| Lidocaine | Lidocaine | 45 | 14 |
| Sertraline Hcl | Sertraline Hcl | 45 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 44 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Acyclovir | Acyclovir | 41 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 41 | 11 |
| Risperidone | Risperidone | 40 | suppressed |
| Dutasteride | Dutasteride | 39 | suppressed |
| Benzonatate | Benzonatate | 38 | 18 |
| Cilostazol | Cilostazol | 37 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 37 | 30 |
| Gemtesa | Vibegron | 36 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 12 |
| Ozempic | Semaglutide | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 29 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 29 | 12 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Cyclosporine | Cyclosporine | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | 20 |
| Entecavir | Entecavir | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 11 |
| Promethazine-Dm | Promethazine/Dextromethorphan | 26 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 23 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Gavilyte-C | Peg3350/Sod Sulf,bicarb,cl/Kcl | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Xiidra | Lifitegrast | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Proctozone-Hc | Hydrocortisone | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $489.92 · 23 records | Gilead Sciences, Inc. | AVANTI, BREZTRI, Intracept, Kerendia, MAVYRET, MYNX CONTROL, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error